ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Wedbush PacGrow Healthcare Conference being held August 13-14, 2024 in New York City. Company management will participate in one-on-one meetings with investors on Wednesday, August 14, 2024.

About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.

ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com

ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com

Staff

Recent Posts

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

46 mins ago

Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo” or the “Company”) (OTCQX: SONX), a leading dental technology…

47 mins ago

Outset Medical Reports Second Quarter 2024 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology…

50 mins ago

Medexus Announces Strong Fiscal Q1 2025 Results

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of…

56 mins ago

MARPAI REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Company continues to drive towards profitability TAMPA, Fla., Aug. 7, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or…

56 mins ago

Waystar Reports Second Quarter 2024 Results

Revenue growth of 20% year-over-year Net loss of $27.7 million and non-GAAP net income of…

56 mins ago